Advertisement

Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge

Chapter
First Online:
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1318)

Abstract

By driving the ongoing pandemic of coronavirus disease 2019 (COVID-19), coronaviruses have become a significant change in twenty-first-century medicine, healthcare systems, education, and the global economy. This chapter rapidly reviews the origin, immunopathogenesis, epidemiology, diagnosis, clinical manifestations, and potential therapeutics of COVID-19. It would also explore the effects of the introduction of a single virus, the so-called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the public health preparedness planning.

Keywords

Borderless Coronavirus COVID-19 Global Immune system Pandemic SARS-CoV-2 
This is a preview of subscription content, log in to check access.

References

  1. Abdullah AS, Tomlinson B, Cockram CS, Thomas GN (2003) Lessons from the severe acute respiratory syndrome outbreak in Hong Kong. Emerg Infect Dis 9(9):1042PubMedPubMedCentralGoogle Scholar
  2. Açikgöz Ö, Günay A (2020) The early impact of the Covid-19 pandemic on the global and Turkish economy. Turk J Med Sci 50(SI-1):520–526.  https://doi.org/10.3906/sag-2004-6CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ahmadi M, Saffarzadeh N, Habibi MA, Hajiesmaeili F, Rezaei N (2020, Jann 1) Colon cancer and SARS-CoV-2: impact of ACE2 expression in susceptibility to COVID-19. bioRxivGoogle Scholar
  4. Ahmed W, Angel N, Edson J, Bibby K, Bivins A, O’Brien JW, Choi PM, Kitajima M, Simpson SL, Li J (2020) First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community. Sci Total Environ 728:138764PubMedPubMedCentralGoogle Scholar
  5. Anyane-Yeboa A, Sato T, Sakuraba A (2020) Racial disparities in COVID-19 deaths reveal harsh truths about structural inequality in america. J Intern Med 288:479.  https://doi.org/10.1111/joim.13117CrossRefPubMedGoogle Scholar
  6. Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM (2020) Coronavirus disease 19 (COVID-19): implications for clinical dental care. J Endod 46(5):584–595.  https://doi.org/10.1016/j.joen.2020.03.008CrossRefPubMedPubMedCentralGoogle Scholar
  7. Babaha F, Rezaei N (2020) Primary immunodeficiency diseases in COVID-19 pandemic: a predisposing or protective factor? Am J Med Sci.  https://doi.org/10.1016/j.amjms.2020.07.027
  8. Bahrami A, Vafapour M, Moazzami B, Rezaei N (2020, Jul 8) Hyperinflammatory shock related to COVID‐19 in a patient presenting with multisystem inflammatory syndrome in children: first case from Iran. J Paediatr Child HealthGoogle Scholar
  9. Banerjee D (2020) ‘Age and ageism in COVID-19’: elderly mental health-care vulnerabilities and needs. Asian J Psychiatr 51:102154.  https://doi.org/10.1016/j.ajp.2020.102154CrossRefPubMedPubMedCentralGoogle Scholar
  10. Basiri A, Heidari A, Nadi MF, Fallahy MTP, Nezamabadi SS, Sedighi M, Saghazadeh A, Rezaei N (2020a) Microfluidic devices for detection of RNA viruses. Rev Med Virol n/a (n/a):e2154.  https://doi.org/10.1002/rmv.2154
  11. Basiri A, Pazhouhnia Z, Beheshtizadeh N, Hoseinpour M, Saghazadeh A, Rezaei N (2020b, Jun 20) Regenerative medicine in COVID-19 treatment: real opportunities and range of promises. Stem Cell Rev Rep 20:1–13Google Scholar
  12. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T (2020) Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis 20:911.  https://doi.org/10.1016/S1473-3099(20)30287-5CrossRefPubMedPubMedCentralGoogle Scholar
  13. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 395:912PubMedPubMedCentralGoogle Scholar
  14. Bulut C, Kato Y (2020) Epidemiology of COVID-19. Turk J Med Sci 50(SI-1):563–570.  https://doi.org/10.3906/sag-2004-172CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799.  https://doi.org/10.1056/NEJMoa2001282CrossRefPubMedGoogle Scholar
  16. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, Kanji JN, Zelyas N, Damji KF, Solarte C (2020) Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol 55:e125.  https://doi.org/10.1016/j.jcjo.2020.03.003CrossRefPubMedPubMedCentralGoogle Scholar
  17. Chen L, Xiong J, Bao L, Shi Y (2020) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 20(4):398–400.  https://doi.org/10.1016/S1473-3099(20)30141-9CrossRefPubMedPubMedCentralGoogle Scholar
  18. Cherry JD (2004) The chronology of the 2002–2003 SARS mini pandemic. Paediatr Respir Rev 5(4):262–269PubMedPubMedCentralGoogle Scholar
  19. Chow KYC, Hon CC, Hui RKH, Wong RTY, Yip CW, Zeng F, Leung FCC (2003) Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Genomics Proteomics Bioinformatics 1(4):247–262PubMedPubMedCentralGoogle Scholar
  20. Clem AS (2011) Fundamentals of vaccine immunology. J Global Infect Dis 3(1):73–78.  https://doi.org/10.4103/0974-777X.77299CrossRefGoogle Scholar
  21. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S, Schneider J, Schmidt ML (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25(3):2000045PubMedCentralGoogle Scholar
  22. Cowling BJ, Leung GM (2020) Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak. Eurosurveillance 25(6):2000110PubMedCentralGoogle Scholar
  24. Darbeheshti F, Rezaei N (2020) Genetic predisposition models to COVID-19 infection. Med Hypotheses 142:109818PubMedPubMedCentralGoogle Scholar
  25. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827PubMedPubMedCentralGoogle Scholar
  26. Doraiswamy S, Cheema S, Mamtani R (2020) Older people and epidemics: a call for empathy. Age Ageing 49(3):493–493PubMedPubMedCentralGoogle Scholar
  27. Dowell SF, Ho MS (2004) Seasonality of infectious diseases and severe acute respiratory syndrome-what we don’t know can hurt us. Lancet Infect Dis 4(11):704–708.  https://doi.org/10.1016/S1473-3099(04)01177-6CrossRefPubMedPubMedCentralGoogle Scholar
  28. Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, Lahiri D, Lavie CJ (2020) Psychosocial impact of COVID-19. Diabetes Metab Syndr 14:779.  https://doi.org/10.1016/j.dsx.2020.05.035CrossRefPubMedPubMedCentralGoogle Scholar
  29. Fan EX (2003) SARS: economic impacts and implications. Asian Development Bank, ManilaGoogle Scholar
  30. Fathi N, Rezaei N (2020) Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int 44:1792PubMedGoogle Scholar
  31. Faye O, Faye O, Dupressoir A, Weidmann M, Ndiaye M, Sall AA (2008) One-step RT-PCR for detection of Zika virus. J Clin Virol 43(1):96–101PubMedGoogle Scholar
  32. Fernandes N (2020) Economic effects of coronavirus outbreak (COVID-19) on the World Economy SSRN: https://ssrn.com/abstract=3557504 or  https://doi.org/10.2139/ssrn.3557504
  33. Fintelman-Rodrigues N, Sacramento CQ, Lima CR, da Silva FS, Ferreira A, Mattos M, de Freitas CS, Soares VC, Dias SD, Temerozo JR, Miranda M (2020, Jan 1) Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production. bioRxivGoogle Scholar
  34. Gandhi M, Yokoe DS, Havlir DV (2020) Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med 382(22):2158–2160.  https://doi.org/10.1056/NEJMe2009758CrossRefPubMedGoogle Scholar
  35. Ghosh R, Dubey MJ, Chatterjee S, Dubey S (2020) Impact of COVID-19 on children: special focus on psychosocial aspect. Education 31:34Google Scholar
  36. Goscé L, Phillips PA, Spinola P, Gupta DRK, Abubakar PI (2020) Modelling SARS-COV2 spread in London: approaches to lift the lockdown. J Infect 81:260.  https://doi.org/10.1016/j.jinf.2020.05.037CrossRefPubMedPubMedCentralGoogle Scholar
  37. Gralinski LE, Menachery VD (2020) Return of the coronavirus: 2019-nCoV. Viruses 12(2):135.  https://doi.org/10.3390/v12020135CrossRefPubMedCentralGoogle Scholar
  38. Gu J, Han B, Wang J (2020) COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology 158(6):1518–1519PubMedGoogle Scholar
  39. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, Liu X-q, Chen R-c, Tang C-l, Wang T, Ou C-q, Li L, Chen P-y, Sang L, Wang W, Li J-f, Li C-c, Ou L-m, Cheng B, Xiong S, Ni Z-y, Xiang J, Hu Y, Liu L, Shan H, Lei C-l, Peng Y-x, Wei L, Liu Y, Hu Y-h, Peng P, Wang J-m, Liu J-y, Chen Z, Li G, Zheng Z-j, Qiu S-q, Luo J, Ye C-j, Zhu S-y, Cheng L-l, Ye F, Li S-y, Zheng J-p, Zhang N-f, Zhong N-s, He J-x (2020a) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55(5):2000547.  https://doi.org/10.1183/13993003.00547-2020CrossRefPubMedPubMedCentralGoogle Scholar
  40. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui DSC, Du B, Li L-j, Zeng G, Yuen K-Y, Chen R-c, Tang C-l, Wang T, Chen P-y, Xiang J, Li S-y, Wang J-l, Liang Z-j, Peng Y-x, Wei L, Liu Y, Hu Y-h, Peng P, Wang J-m, Liu J-y, Chen Z, Li G, Zheng Z-j, Qiu S-q, Luo J, Ye C-j, Zhu S-y, Zhong N-s (2020b) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720.  https://doi.org/10.1056/NEJMoa2002032CrossRefPubMedGoogle Scholar
  41. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D (2020) Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. Am J Roentgenol 215:1–6.  https://doi.org/10.2214/AJR.20.22961CrossRefGoogle Scholar
  42. Hanaei S, Rezaei N (2020) COVID-19: developing from an outbreak to a pandemic. Arch Med Res 51:582PubMedPubMedCentralGoogle Scholar
  43. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA (2020) The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med 9(4):1225.  https://doi.org/10.3390/jcm9041225CrossRefPubMedCentralGoogle Scholar
  44. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O (2020) On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheum 72:1059Google Scholar
  45. Hessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, Abrotan S, Shojaei L, Sedighi S, Shamshirian D, Rezaei N (2020, Oct 16) Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am J Emerg MedGoogle Scholar
  46. Hirbod-Mobarakeh A, Mahmoudi M, Rezaei N (2014) Nutrition, immunity, and aging. In: Immunology of aging. Springer, Berlin, pp 263–284Google Scholar
  47. Hiscott J, Alexandridi M, Muscolini M, Tassone E, Palermo E, Soultsioti M, Zevini A (2020) The global impact of the coronavirus pandemic. Cytokine Growth Factor Rev 53:1.  https://doi.org/10.1016/j.cytogfr.2020.05.010CrossRefPubMedPubMedCentralGoogle Scholar
  48. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, Wu Y, Sun L, Xu Y (2020) Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol 127:104371PubMedPubMedCentralGoogle Scholar
  49. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020a) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London) 395(10223):497–506.  https://doi.org/10.1016/s0140-6736(20)30183-5CrossRefGoogle Scholar
  50. Huang X, Wei F, Hu L, Wen L, Chen K (2020b) Epidemiology and clinical characteristics of COVID-19. Arch Iran Med March 23(4):268–271.  https://doi.org/10.34172/aim.2020.09CrossRefGoogle Scholar
  51. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y (2020) Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395(10238):1695–1704.  https://doi.org/10.1016/S0140-6736(20)31042-4CrossRefPubMedPubMedCentralGoogle Scholar
  52. Jabbari P, Rezaei N (2020) With risk of reinfection, is COVID-19 here to stay? Disaster Med Public Health Prep:1.  https://doi.org/10.1017/dmp.2020.274
  53. Jabbari P, Jabbari F, Ebrahimi S, Rezaei N (2020, Jun) COVID-19: a chimera of two pandemics. Disaster Med Public Health Prep 14(3):e38–9Google Scholar
  54. Jahanshahlu L, Rezaei N (2020a) Central nervous system involvement in COVID-19. Arch Med Res 51:721PubMedPubMedCentralGoogle Scholar
  55. Jahanshahlu L, Rezaei N (2020b) Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother 129:110337PubMedPubMedCentralGoogle Scholar
  56. Jeong H, Yim HW, Song Y-J, Ki M, Min J-A, Cho J, Chae J-H (2016) Mental health status of people isolated due to middle east respiratory syndrome. Epidemiol Health 38:e2016048PubMedPubMedCentralGoogle Scholar
  57. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, Park JH, Na HK, Oh M-d (2020) The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci 35(5):e61PubMedPubMedCentralGoogle Scholar
  58. Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, Wu J, Du H, Chen T, Li R (2020) Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open 3(3):e203976–e203976PubMedPubMedCentralGoogle Scholar
  59. Lau JT, Tsui H, Lau M, Yang X (2004) SARS transmission, risk factors, and prevention in Hong Kong. Emerg Infect Dis 10(4):587PubMedPubMedCentralGoogle Scholar
  60. Leung K, Wu JT, Liu D, Leung GM (2020) First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet 395(10233):1382–1393.  https://doi.org/10.1016/S0140-6736(20)30746-7CrossRefPubMedPubMedCentralGoogle Scholar
  61. Li J-Y, You Z, Wang Q, Zhou Z-J, Qiu Y, Luo R, Ge X-Y (2020a) The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 22(2):80–85.  https://doi.org/10.1016/j.micinf.2020.02.002CrossRefPubMedPubMedCentralGoogle Scholar
  62. Li X, Geng M, Peng Y, Meng L, Lu S (2020b) Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 10(2):102–108.  https://doi.org/10.1016/j.jpha.2020.03.001CrossRefPubMedPubMedCentralGoogle Scholar
  63. Lipsitch M, Swerdlow DL, Finelli L (2020) Defining the epidemiology of Covid-19—studies needed. N Engl J Med 382(13):1194–1196PubMedGoogle Scholar
  64. Liu P, Jiang J-Z, Wan X-F, Hua Y, Li L, Zhou J, Wang X, Hou F, Chen J, Zou J, Chen J (2020a) Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? PLoS Pathog 16(5):e1008421.  https://doi.org/10.1371/journal.ppat.1008421CrossRefPubMedPubMedCentralGoogle Scholar
  65. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L (2020b) Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 92:595.  https://doi.org/10.1002/jmv.25726CrossRefPubMedGoogle Scholar
  66. Lotfi M, Rezaei N (2020) SARS-CoV-2: a comprehensive review from pathogenicity of the virus to clinical consequences. J Med Virol 92:1864PubMedGoogle Scholar
  67. Lotfi M, Hamblin MR, Rezaei N (2020) COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 508:254PubMedPubMedCentralGoogle Scholar
  68. Lovato A, de Filippis C (2020) Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J 99:569.:0145561320920762.  https://doi.org/10.1177/0145561320920762CrossRefPubMedGoogle Scholar
  69. Lu C-C, Chen M-Y, Chang Y-L (2020) Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc Latest Articles 83:534Google Scholar
  70. Luan J, Lu Y, Jin X, Zhang L (2020) Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun 526(1):165–169.  https://doi.org/10.1016/j.bbrc.2020.03.047CrossRefPubMedPubMedCentralGoogle Scholar
  71. Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L (2020) Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020:2020020407Google Scholar
  72. Lurie N, Saville M, Hatchett R, Halton J (2020) Developing Covid-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973.  https://doi.org/10.1056/NEJMp2005630CrossRefPubMedGoogle Scholar
  73. Mahmoudi M, Rezaei N (2019) Nutrition and immunity. Springer, ChamGoogle Scholar
  74. Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N (2020) The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci 258:118185.  https://doi.org/10.1016/j.lfs.2020.118185CrossRefPubMedPubMedCentralGoogle Scholar
  75. Masters PS (2006) The molecular biology of coronaviruses. Adv Virus Res 66:193–292PubMedPubMedCentralGoogle Scholar
  76. McKee M, Stuckler D (2020) If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med 26(5):640–642.  https://doi.org/10.1038/s41591-020-0863-yCrossRefPubMedGoogle Scholar
  77. medicine USnlo (2020a) BCG vaccination to protect healthcare workers against COVID-19 (BRACE). https://clinicaltrials.gov/ct2/show/NCT04327206
  78. medicine USnlo (2020b) Reducing health care workers absenteeism in Covid-19 pandemic through BCG vaccine (BCG-CORONA). https://clinicaltrials.gov/ct2/show/NCT04328441
  79. Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet.  https://doi.org/10.1016/S0140-6736(20)31180-6
  80. Miller AM (2020) How you should prepare for a potential ‘second wave’ of the coronavirus, according to experts. Business Insider France. https://www.businessinsider.fr/graphique-du-jour-titres-les-plus-ecoutes-sur-spotify-2017. Accessed 25 May 2020
  81. Mirbeyk M, Rezaei N (2020) The impact of COVID-19 on pregnancy and neonatal health: a systematic reviewGoogle Scholar
  82. Moazzami B, Razavi-Khorasani N, Moghadam AD, Farokhi E, Rezaei N (2020) COVID-19 and telemedicine: immediate action required for maintaining healthcare providers Well-being. J Clin Virol 126:104345PubMedPubMedCentralGoogle Scholar
  83. Mohamed K, Rodríguez-Román E, Rahmani F, Zhang H, Ivanovska M, Makka SA, Joya M, Makuku R, Islam MS, Radwan N (2020a) Borderless collaboration is needed for COVID-19—a disease that knows no borders. Infect Control Hosp Epidemiol 41:1–2Google Scholar
  84. Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N (2020b) Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review. Bioinorg Chem 104490.  https://doi.org/10.1016/j.bioorg.2020.104490
  85. Momtazmanesh S, Ochs HD, Uddin LQ, Perc M, Routes JM, Vieira DN, Al-Herz W, Baris S, Prando C, Rosivall L (2020) All together to fight COVID-19. Am J Trop Med Hyg 102(6):1181–1183PubMedPubMedCentralGoogle Scholar
  86. Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, Martin ET, Petrie JG (2020) Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J Infect Dis 222:9.  https://doi.org/10.1093/infdis/jiaa161CrossRefPubMedPubMedCentralGoogle Scholar
  87. Moradian N, Ochs HD, Sedikies C, Hamblin MR, Camargo CA, Martinez JA, Biamonte JD, Abdollahi M, Torres PJ, Nieto JJ (2020) The urgent need for integrated science to fight COVID-19 pandemic and beyond. J Transl Med 18(1):1–7Google Scholar
  88. Nasab MG, Saghazadeh A, Rezaei N (2020) SARS-CoV-2-a tough opponent for the immune system. Arch Med Res 51:589.  https://doi.org/10.1016/j.arcmed.2020.05.020CrossRefPubMedPubMedCentralGoogle Scholar
  89. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R (2020) The socio-economic implications of the coronavirus and COVID-19 pandemic: a review. Int J Surg 78:185.:S1743-9191(1720)30316-30312.  https://doi.org/10.1016/j.ijsu.2020.04.018CrossRefPubMedPubMedCentralGoogle Scholar
  90. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-M, Hayashi K, Kinoshita R, Yang Y, Yuan B, Akhmetzhanov AR, Linton NM (2020) Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 94:154–155.  https://doi.org/10.1016/j.ijid.2020.03.020CrossRefPubMedPubMedCentralGoogle Scholar
  91. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S (2020) Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol: J Mol Epidemiol Evol Genet Infect Dis 79:104212.  https://doi.org/10.1016/j.meegid.2020.104212CrossRefGoogle Scholar
  92. Park M, Cook AR, Lim JT, Sun Y, Dickens BL (2020) A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 9(4):967PubMedCentralGoogle Scholar
  93. Pashaei M, Rezaei N (2020) Immunotherapy for SARS-CoV-2: potential opportunities. Expert Opin Biol Ther 20:1–5.  https://doi.org/10.1080/14712598.2020.1807933CrossRefGoogle Scholar
  94. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U (2020) The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 49:717PubMedGoogle Scholar
  95. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B (2020) Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci 12(1):1–6Google Scholar
  96. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E (2020) COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 26:729PubMedPubMedCentralGoogle Scholar
  97. Podile AR, Basu A (2020) Opportunities, challenges and directions in science and technology for tackling COVID-19. Trans Indian Natl Acad Eng 5:1–5.  https://doi.org/10.1007/s41403-020-00111-zCrossRefGoogle Scholar
  98. Pourahmad R, Moazzami B, Rezaei N (2020) Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19. SN Compr Clin Med 2:1407–1411.  https://doi.org/10.1007/s42399-020-00438-2
  99. Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38(1):1–9PubMedGoogle Scholar
  100. Rabiee N, Rabiee M, Bagherzadeh M, Rezaei N (2020) COVID-19 and picotechnology: potential opportunities. Med Hypotheses 144:109917PubMedPubMedCentralGoogle Scholar
  101. Rashid ZZ, Othman SN, Samat MNA, Ali UK, Wong KK (2020) Diagnostic performance of COVID-19 serology assays. Malays J Pathol 42(1):13–21Google Scholar
  102. Rezaei N (2020a) COVID-19 affects healthy pediatricians more than pediatric patients. Infect Control Hosp Epidemiol 41:1.  https://doi.org/10.1017/ice.2020.139CrossRefGoogle Scholar
  103. Rezaei N (2020b) COVID-19 and medical biotechnology. Avicenna J Med Biotechnol 12(3):139PubMedPubMedCentralGoogle Scholar
  104. Richard Baldwin BWDM (2020, March 06) Economics in the time of COVID-19. A VoxEU.org Book, CEPR Press
  105. Robertson E, Hershenfield K, Grace SL, Stewart DE (2004) The psychosocial effects of being quarantined following exposure to SARS: a qualitative study of Toronto health care workers. Can J Psychiatr 49(6):403–407Google Scholar
  106. Rokni M, Hamblin MR, Rezaei N (2020) Cytokines and COVID-19: friends or foes? Hum Vaccin Immunother 16:1–3Google Scholar
  107. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382(10):970–971PubMedPubMedCentralGoogle Scholar
  108. Rubin GJ, Wessely S (2020) The psychological effects of quarantining a city. BMJ 368:m313PubMedGoogle Scholar
  109. Rzymski P, Nowicki M, Mullin GE, Abraham A, Rodríguez-Román E, Petzold MB, Bendau A, Sahu KK, Ather A, Naviaux A-F (2020) Quantity does not equal quality: scientific principles cannot be sacrificed. Int Immunopharmacol 86:106711PubMedPubMedCentralGoogle Scholar
  110. Sabino-Silva R, Jardim ACG, Siqueira WL (2020) Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig 24(4):1619–1621PubMedGoogle Scholar
  111. Saghazadeh A, Rezaei N (2017) Implications of toll-like receptors in Ebola infection. Expert Opin Ther Targets 21(4):415–425PubMedGoogle Scholar
  112. Saghazadeh A, Rezaei N (2019) In: Rezaei N (ed) Introductory chapter: immunogenetics, immunogenetics. IntechOpen.  https://doi.org/10.5772/intechopen.85505. Available from: https://www.intechopen.com/books/immunogenetics/introductory-chapter-immunogenetics
  113. Saghazadeh A, Rezaei N (2020a) Immune-epidemiological parameters of the novel coronavirus – a perspective. Expert Rev Clin Immunol 16(5):465–470.  https://doi.org/10.1080/1744666x.2020.1750954
  114. Saghazadeh A, Rezaei N (2020b) Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol 84:106560.  https://doi.org/10.1016/j.intimp.2020.106560CrossRefPubMedPubMedCentralGoogle Scholar
  115. Sahu KK, Siddiqui AD, Rezaei N, Cerny J (2020) Challenges for management of immune thrombocytopenia during COVID-19 pandemic. J Med Virol 92:2277PubMedGoogle Scholar
  116. Saleki K, Banazadeh M, Saghazadeh A, Rezaei N (2020) The involvement of the central nervous system in patients with COVID-19. Reviews in the Neurosciences 1, no. ahead-of-printGoogle Scholar
  117. Sanchez E (2020) COVID-19 science: why testing is so important. American Heart Association. https://www.heart.org/en/news/2020/04/02/covid-19-science-why-testing-is-so-important. Accessed 25 May 2020
  118. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323(18):1824–1836.  https://doi.org/10.1001/jama.2020.6019CrossRefPubMedGoogle Scholar
  119. Shamshirian D, Rezaei N (2020) Cardiovascular diseases burden in COVID-19: systematic review and meta-analysisGoogle Scholar
  120. Sharifkashani S, Bafrani MA, Khaboushan AS, Pirzadeh M, Kheirandish A, Yavarpour Bali H, Hessami A, Saghazadeh A, Rezaei N (2020) Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: potential therapeutic targeting. Eur J Pharmacol 884:173455.  https://doi.org/10.1016/j.ejphar.2020.173455CrossRefPubMedPubMedCentralGoogle Scholar
  121. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 24:91–98.  https://doi.org/10.1016/j.jare.2020.03.005CrossRefPubMedPubMedCentralGoogle Scholar
  122. Sim K, Chua HC (2004) The psychological impact of SARS: a matter of heart and mind. CMAJ 170(5):811–812PubMedPubMedCentralGoogle Scholar
  123. Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, Talbot PJ, Tam T, Babiuk L (2005) Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56:357–381PubMedGoogle Scholar
  124. Song P, Karako T (2020) COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends 14:1PubMedGoogle Scholar
  125. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P (2020) Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA 323(20):2089–2090.  https://doi.org/10.1001/jama.2020.6771CrossRefPubMedPubMedCentralGoogle Scholar
  126. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24(6):490–502.  https://doi.org/10.1016/j.tim.2016.03.003CrossRefPubMedPubMedCentralGoogle Scholar
  127. Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, Yi F, Yang H-C, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98(1):219–227.  https://doi.org/10.1016/j.kint.2020.04.003CrossRefPubMedPubMedCentralGoogle Scholar
  128. Sun LH (2020) CDC director warns second wave of coronavirus is likely to be even more devastating. The Washington Post. https://www.washingtonpost.com/health/2020/04/21/coronavirus-secondwave-cdcdirector/. Accessed 25 May 2020
  129. Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, Mayhew S (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19(5):305–306.  https://doi.org/10.1038/d41573-020-00073-5CrossRefPubMedGoogle Scholar
  130. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao S-Y (2020) Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 33:1–8Google Scholar
  131. Todd B (2020) Where are the masks? Am J Nurs 120(6):18–19.  https://doi.org/10.1097/01.NAJ.0000668700.23009.1eCrossRefPubMedGoogle Scholar
  132. Verch T, Trausch JJ, Shank-Retzlaff M (2018) Principles of vaccine potency assays. Bioanalysis 10(3):163–180.  https://doi.org/10.4155/bio-2017-0176CrossRefPubMedGoogle Scholar
  133. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 20:669PubMedPubMedCentralGoogle Scholar
  134. Wang M, Yan M, Xu H, Liang W, Kan B, Zheng B, Chen H, Zheng H, Xu Y, Zhang E (2005) SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 11(12):1860PubMedPubMedCentralGoogle Scholar
  135. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395(10236):1569–1578.  https://doi.org/10.1016/S0140-6736(20)31022-9CrossRefPubMedPubMedCentralGoogle Scholar
  136. Wang F, Kream RM, Stefano GB (2020a) An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit 26:e924700.  https://doi.org/10.12659/msm.924700CrossRefPubMedPubMedCentralGoogle Scholar
  137. Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W (2020b) Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord 13:1756286420917830.  https://doi.org/10.1177/1756286420917830CrossRefPubMedPubMedCentralGoogle Scholar
  138. Wang S, Wen X, Liu B, Dong Y, Cui M (2020c) Psychological influence of Coronovirus disease 2019 (COVID-19) pandemic on the general public, medical workers and patients with mental disorders and its countermeasures. Psychosomatics.  https://doi.org/10.1016/j.psym.2020.05.005
  139. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou J-J, Li N, Guo Y, Li X, Shen X, Zhang Z, Shu F, Huang W, Li Y, Zhang Z, Chen R-A, Wu Y-J, Peng S-M, Huang M, Xie W-J, Cai Q-H, Hou F-H, Liu Y, Chen W, Xiao L, Shen Y (2020) Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins. bioRxiv:2020.2002.2017.951335.  https://doi.org/10.1101/2020.02.17.951335
  140. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J (2020a) Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 296:E41. 200343PubMedGoogle Scholar
  141. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, Yang L, Fu S, Wang R (2020b) Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect:S0163–4453(0120)30172–30179.  https://doi.org/10.1016/j.jinf.2020.03.044
  142. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422PubMedPubMedCentralGoogle Scholar
  143. Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, Zhao H, Lester E, Wu T, Pang CH (2020) The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: recent advances, prevention, and treatment. Int J Environ Res Public Health 17(7):2323.  https://doi.org/10.3390/ijerph17072323CrossRefPubMedCentralGoogle Scholar
  144. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, Dean N, Longini I, Halloran ME, Xu B, Zhang X (2020, Jan 1) Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxivGoogle Scholar
  145. Yao H, Chen J-H, Xu Y-F (2020) Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 7(4):e21PubMedPubMedCentralGoogle Scholar
  146. Yazdanpanah F, Hamblin MR, Rezaei N (2020a) The immune system and COVID-19: friend or foe? Life Sci 256:117900.  https://doi.org/10.1016/j.lfs.2020.117900CrossRefPubMedPubMedCentralGoogle Scholar
  147. Yazdanpanah N, Saghazadeh A, Rezaei N (2020b) Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19). Rev Neurosci 31:691.  https://doi.org/10.1515/revneuro-2020-0039CrossRefPubMedGoogle Scholar
  148. Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of theCytokine Storm’in COVID-19. J Infect 80(6):607–613PubMedPubMedCentralGoogle Scholar
  149. Yousefzadegan S, Rezaei N (2020) Case report: death due to COVID-19 in three brothers. Am J Trop Med Hyg 102(6):1203–1204PubMedPubMedCentralGoogle Scholar
  150. Yuan J, Hon C-C, Li Y, Wang D, Xu G, Zhang H, Zhou P, Poon LL, Lam TT-Y, Leung FC-C (2010) Intraspecies diversity of SARS-like coronaviruses in Rhinolophus sinicus and its implications for the origin of SARS coronaviruses in humans. J Gen Virol 91(4):1058–1062PubMedGoogle Scholar
  151. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z (2020a) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17(5):533–535PubMedPubMedCentralGoogle Scholar
  152. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X (2020b) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17(5):259–260PubMedGoogle Scholar
  153. Zhong NS, Zeng GQ (2008) Pandemic planning in China: applying lessons from severe acute respiratory syndrome. Respirology 13:S33–S35.  https://doi.org/10.1111/j.1440-1843.2008.01255.x
  154. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD (2020a) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. Cold Spring Harb Lab 2020:22–914952Google Scholar
  155. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020b) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273.  https://doi.org/10.1038/s41586-020-2012-7CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s), under exclusive license to Springer Nature Switzerland AG 2021

Authors and Affiliations

  1. 1.Universal Scientific Education and Research Network (USERN)TehranIran
  2. 2.Research Center for Immunodeficiencies, Children’s Medical CenterTehran University of Medical SciencesTehranIran
  3. 3.Research Institute of Applied Sciences, Academic Center of Education, Culture and Research (ACECR)Shahid Beheshti UniversityTehranIran
  4. 4.School of MedicineTehran University of Medical SciencesTehranIran
  5. 5.USC Institute of Urology, USC/Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  6. 6.Shahid Beheshti UniversityTehranIran
  7. 7.School of MedicineShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations

Cite chapter

Buy options